Xilio Therapeutics, Inc.
XLO
$0.709
$0.00881.26%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.34M | 4.62M | 2.36M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.34M | 4.62M | 2.36M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.34M | 4.62M | 2.36M | -- | -- |
| SG&A Expenses | 24.78M | 24.66M | 24.66M | 25.74M | 27.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.99M | 68.77M | 69.06M | 72.15M | 79.13M |
| Operating Income | -59.65M | -64.15M | -66.70M | -72.15M | -79.13M |
| Income Before Tax | -58.24M | -62.80M | -65.53M | -70.96M | -76.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.24 | -62.80 | -65.53 | -70.96 | -76.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.24M | -62.80M | -65.53M | -70.96M | -76.40M |
| EBIT | -59.65M | -64.15M | -66.70M | -72.15M | -79.13M |
| EBITDA | -58.00M | -62.43M | -64.91M | -70.30M | -77.23M |
| EPS Basic | -1.36 | -1.79 | -2.18 | -2.57 | -2.78 |
| Normalized Basic EPS | -0.83 | -1.10 | -1.34 | -1.59 | -1.74 |
| EPS Diluted | -1.36 | -1.80 | -2.19 | -2.57 | -2.78 |
| Normalized Diluted EPS | -0.83 | -1.10 | -1.34 | -1.59 | -1.74 |
| Average Basic Shares Outstanding | 200.01M | 162.89M | 126.95M | 110.46M | 109.98M |
| Average Diluted Shares Outstanding | 200.01M | 162.89M | 126.95M | 110.46M | 109.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
